Nutex Health Inc. Common Stock (NUTX)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with the business. Nutex runs micro-hospitals and specialty hospitals, including emergency, inpatient and behavioral care. The turnaround label FairStock computes fits: it lost $45.8M in fiscal year 2023 (period ended 2023-12-31), earned $52.1M in fiscal year 2024 (period ended 2024-12-31) and $70.8M in fiscal year 2025 (period ended 2025-12-31). In fiscal Q2 2026 (quarter ended 2026-06-30), it reported revenue of $210.8M, net income of $65.8M and diluted EPS of $9.38. That is real profitability, not just a story. FairStock also shows trailing free cash flow of $274.2M and a 19.6% FCF yield, with ROE of 64.56%, ROCE of 33.32% and a Piotroski score of 7/9. At the 2026-10-13 close of $204.36, market cap is $1.4B, P/E is 7.92 and EV/EBITDA is 4.01, which looks cheap if those earnings persist. But I see no clear moat in the provided figures, and growth is uneven: fiscal Q2 2026 revenue of $210.8M was below fiscal Q2 2025 revenue of $244.0M, though that prior-year quarter had a $17.7M net loss. The Graham Number is $182.89, so the price carries an -11.74% margin of safety, and P/B is 3.55. Debt-to-equity is 0.68 and beta is 2.02. I would want consistent cash generation and asset protection before calling this a classic value bargain.

In plain English: Nutex Health runs a network of small specialty hospitals and emergency-care facilities. The business has swung to strong profits and produces a lot of cash, but sales in the latest quarter were lower than a year earlier and the record is uneven. At the latest close, the stock looks inexpensive compared with its profits, but expensive compared with the value of its net assets and a conservative asset-based estimate.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer